Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BICOV-1 intraperitoneal chemotherapy after interval surgery in ovarian cancer
2022-502691-23-00Phase 4Authorised
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel and cisplatin in ovarian cancer, sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoints: Postoperative morbidity, Postoperative mortality and 2 more. Planned start Jun 2023; status: authorised.
02
Drugs
paclitaxelcisplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2022-502691-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502691-23-00.